What question did this study set out to answer?

To evaluate the effectiveness of Bevacizumab and Fingolimod in inducing cell death in OVCA-3 cells.

March 3, 2026

Bevacizumab and Fingolimod Combination Therapy Induce Cytotoxicity and Apoptosis in Ovcar-3 Cells

To evaluate the effectiveness of Bevacizumab and Fingolimod in inducing cell death in OVCA-3 cells.
Combination therapy of Bevacizumab and Fingolimod applied to OVCA-3 cell line
Assessment of cytotoxicity and apoptosis rates
Comparison of treated versus untreated control cells
Combination increased cytotoxicity in OVCA-3 cells compared to single treatments
Significant apoptosis observed in cells treated with both drugs
Indication of enhanced cancer treatment efficacy through combination approach

The combination of Bevacizumab and Fingolimod presents a promising treatment strategy for ovarian cancer.

Bookmark